NASDAQ:BCPC - Balchem Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $157.33
  • Forecasted Upside: 20.68 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$130.37
▲ +0.63 (0.49%)

This chart shows the closing price for BCPC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Balchem Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCPC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCPC

Analyst Price Target is $157.33
▲ +20.68% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Balchem in the last 3 months. The average price target is $157.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 20.68% upside from the last price of $130.37.

This chart shows the closing price for BCPC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Balchem. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2022HC WainwrightLower Price TargetBuy$155.00 ➝ $152.00Medium
3/8/2022HC WainwrightLower Price TargetBuy$170.00 ➝ $155.00Medium
2/22/2022SidotiUpgradeNeutral ➝ Buy$175.00Medium
1/10/2022HC WainwrightBoost Price TargetBuy$160.00 ➝ $170.00High
11/29/2021SidotiDowngradeBuy ➝ Neutral$175.00Medium
8/2/2021StephensDowngradeOverweight ➝ Equal Weight$140.00 ➝ $145.00High
8/2/2021HC WainwrightBoost Price TargetBuy$145.00 ➝ $160.00High
2/22/2021HC WainwrightBoost Price TargetBuy$126.00 ➝ $145.00High
2/22/2021StephensUpgradeEqual Weight ➝ Overweight$100.00 ➝ $140.00High
8/4/2020HC WainwrightBoost Price TargetBuy$104.00 ➝ $126.00Medium
7/9/2020StephensInitiated CoverageEqual Weight$100.00Medium
5/4/2020HC WainwrightLower Price TargetBuy$116.00 ➝ $104.00High
2/24/2020HC WainwrightLower Price TargetBuy$122.00 ➝ $116.00High
1/31/2020HC WainwrightReiterated RatingBuy$110.00 ➝ $122.00High
11/6/2019HC WainwrightReiterated RatingBuy ➝ Positive$95.00 ➝ $110.00High
8/5/2019HC WainwrightReiterated RatingBuy$110.00 ➝ $95.00High
5/6/2019HC WainwrightReiterated RatingBuy$110.00Low
5/6/2019Pivotal ResearchDowngradeBuy ➝ Hold$100.00High
2/5/2019HC WainwrightSet Price TargetBuy$101.00High
12/10/2018HC WainwrightSet Price TargetBuy$101.00High
11/6/2018Pivotal ResearchUpgradeHold ➝ Buy$95.00 ➝ $100.00Low
10/16/2018SidotiUpgradeNeutral ➝ Buy$127.00High
10/15/2018HC WainwrightSet Price TargetBuy$140.00Low
9/25/2018HC WainwrightInitiated CoverageBuy ➝ BuyLow
8/3/2018Pivotal ResearchBoost Price TargetHold$85.00 ➝ $95.00High
5/7/2018Vertical ResearchDowngradeBuy ➝ HoldMedium
5/7/2018Pivotal ResearchUpgradeSell ➝ Hold$85.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Balchem logo
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
Read More

Today's Range

Now: $130.37
Low: $128.45
High: $130.60

50 Day Range

MA: $122.33
Low: $113.60
High: $130.37

52 Week Range

Now: $130.37
Low: $110.15
High: $174.29

Volume

2,246 shs

Average Volume

132,952 shs

Market Capitalization

$4.19 billion

P/E Ratio

41.79

Dividend Yield

0.49%

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Balchem?

The following Wall Street research analysts have issued stock ratings on Balchem in the last year: HC Wainwright, Sidoti, Stephens, and StockNews.com.
View the latest analyst ratings for BCPC.

What is the current price target for Balchem?

0 Wall Street analysts have set twelve-month price targets for Balchem in the last year. Their average twelve-month price target is $157.33, suggesting a possible upside of 20.7%.
View the latest price targets for BCPC.

What is the current consensus analyst rating for Balchem?

Balchem currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCPC will outperform the market and that investors should add to their positions of Balchem.
View the latest ratings for BCPC.

How do I contact Balchem's investor relations team?

Balchem's physical mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company's listed phone number is (845) 326-5600 and its investor relations email address is [email protected] The official website for Balchem is www.balchem.com. Learn More about contacing Balchem investor relations.